- 1.0Impact Factor
- 2.0CiteScore
- 22 daysTime to First Decision
Automated Technology for Personalized Cancer Medicine: A Theme Issue in Honor of Prof. Dr. Thomas Grogan
Special Issue Information
Dear Colleagues,
This honorary issue celebrates Prof. Thomas Grogan, Emeritus Professor of Pathology at the University of Arizona and founder of Ventana Medical Systems Inc.
Prof Grogan’s scientific work was of great relevance in actively contributing to the development of the WHO classification of tumours of the hemopoietic and lymphoma tissues and his innovations in automated immunohistochemistry technology, as well as pre-analytical tissue processing, allowed him to develop several patents. The impact of these methodologies showed the clinical importance of cancer pathology, as they ensure reliable test results for determining patients’ treatment options. These advances, recognised by pathologists and clinical oncologists, further contributed to elevating the scientific importance of pathology.
We dedicate this honorary Special Issue to Prof. Tom Grogan, entitled "Automated Technology for Personalized Cancer Medicine", highlighting his major professional contributions, including novel development in the fields of immunohistology, in situ hybridization and clinical biomarkers.
The Special Issue will also focus on the impact of automated technologies on diagnostic and molecular pathology, as well as the identification of novel cancer therapies.
Prof. Dr. Teresa Marafioti
Prof. Dr. Annunziata Gloghini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- personalized cancer medicine
- cancer diagnosis
- automated technology
- lymphoma classification
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

